- Home
- NBB vs CLLS Comparison
NBB vs CLLS Comparison
Compare NBB & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBB | CLLS |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.9M | 438.4M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | NBB | CLLS |
|---|---|---|
| Price | $15.81 | $4.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 73.9K | 55.6K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 8.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | N/A | $20.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $13.67 | $1.10 |
| 52 Week High | $16.66 | $5.48 |
Technical Indicators
Market Signals| Indicator | NBB | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 45.53 |
| Support Level | $15.63 | $4.04 |
| Resistance Level | $16.08 | $4.50 |
| Average True Range (ATR) | 0.14 | 0.22 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 32.00 | 35.87 |
Price Performance
Historical ComparisonAbout NBB Nuveen Taxable Municipal Income Fund of Beneficial Interest
Nuveen Taxable Municipal Income Fund is a closed-end fund incorporated in the United States. Its primary objective is current income through investments in taxable municipal securities; the secondary objective is to seek enhanced portfolio value and total return. The fund invests a majority of its assets in a diversified portfolio of taxable municipal securities.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.